Literature DB >> 25001448

Pulpectomy in hyperemic pulp and accelerated root resorption in primary teeth: a review with associated case report.

Tarun Walia1.   

Abstract

Persistent hemorrhage after complete amputation of coronal pulp is a common clinical finding during pulpotomy procedure in primary teeth. These teeth are best managed with pulpectomy, but they have hyperemic pulp with some remaining vital tissue. Good chemico-biomechanical preparation of primary canals cannot guarantee complete removal of this vital tissue from inaccessible areas. Use of Ca(OH) ₂ containing root filling pastes in vital pulp tissue can cause accelerated resorption of primary roots. The possible mechanism behind such extensive root resorption is discussed with review of literature. A case report of a child with 30 months follow-up is presented and discussed.

Entities:  

Mesh:

Year:  2014        PMID: 25001448     DOI: 10.4103/0970-4388.135844

Source DB:  PubMed          Journal:  J Indian Soc Pedod Prev Dent        ISSN: 0970-4388


  4 in total

1.  An in vitro comparison of three delivery techniques for obturation of root canals in primary molars.

Authors:  T Walia; A H Ghanbari; S Mathew; A H Ziadlou
Journal:  Eur Arch Paediatr Dent       Date:  2016-11-24

2.  Therapeutic effects of Pulpotomy and Pulpectomy on deciduous molars with deep caries.

Authors:  Yuxiang Tang; Wantian Xu
Journal:  Pak J Med Sci       Date:  2017 Nov-Dec       Impact factor: 1.088

3.  Improvement of Biological Effects of Root-Filling Materials for Primary Teeth by Incorporating Sodium Iodide.

Authors:  Ji-Myung Choi; Huong Thu Vu; Seong-Jin Shin; Jun-Yong Ahn; You-Jin Kim; Sol Song; Mi-Ran Han; Jun-Haeng Lee; Jong-Soo Kim; Jonathan C Knowles; Hae-Hyoung Lee; Ji-Sun Shin; Jong-Bin Kim; Jung-Hwan Lee
Journal:  Molecules       Date:  2022-05-04       Impact factor: 4.411

4.  Clinical and radiographic evaluation of pulpectomy in primary teeth: a 18-months clinical randomized controlled trial.

Authors:  Xiaoxian Chen; Xinggang Liu; Jie Zhong
Journal:  Head Face Med       Date:  2017-10-27       Impact factor: 2.151

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.